Yep. I hope you are right. I've made the point before that revenues are one thing, but its operating cashflow and ultimately NPAT that matter. R&D and marketing costs can chew up a lot of that revenue and has done so in the past.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.63M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| NET (ASX) Chart |
Day chart unavailable